You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.
By sequencing 72,501 individual kidney cells, researchers saw some shared transcriptional patterns in kidney cancers and developing or adult kidneys.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.
A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.
An international team of researchers compared genetic changes that occur in the blood of people who develop acute myeloid leukemia and those who do not.
The researchers also reported that cholera strains infecting members of the same household were highly similar, suggesting in-household transmissions.
The London School of Hygiene and Tropical Medicine's Sharon Peacock argued a sequencing-based pathogen surveillance approach could uncover outbreaks faster.
Sequencing the genomes of a half a dozen chimp- or gorilla-infecting malaria parasites provided a clearer picture of Plasmodium falciparum evolution.
An analysis of more than 1,000 Neisseria gonorrhoeae genomes provided insights into antibiotic resistance patterns and related genomic features.
Independent research teams identified and sequenced hepatitis B strains going back thousands of years from samples in Europe, uncovering now-extinct lineages.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.